Rituximab Concept

subject area of

• 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis  Academic Article
• A Canadian phase II study evaluating the efficacy of rituximab in the management of patients with relapsed/refractory thrombotic thrombocytopenic purpura  Conference Paper
• A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia  Academic Article
• A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab  Academic Article
• A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia  Academic Article
• A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed ch  Academic Article
• An atypical case of bilateral posterior scleritis in a patient with chronic lymphocytic leukemia  Academic Article
• Anti-cytokine targeted therapies for ANCA-associated vasculitis  Academic Article
• Application of the systematic review and bibliometric network analysis (SeBriNA) methodology contextualizes evidence. Part 2: rituximab for non-Hodgkin's lymphoma  Academic Article
• Autoimmune haemolytic anaemia associated with epstein barr virus infection as a severe late complication after kidney transplantation and successful treatment with rituximab: case report  Academic Article
• Autologous Stem Cell Transplantation in Follicular Lymphoma: a Systematic Review and Meta-analysis  Academic Article
• Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma  Academic Article
• Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group  Academic Article
• Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world  Academic Article
• Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group  Academic Article
• Childhood Immune Thrombocytopenia: A Changing Therapeutic Landscape  Academic Article
• Conference abstracts of a new oncology drug do not always lead to full publication: Proceed with caution  Academic Article
• Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma  Academic Article
• Current Options for the Treatment of Idiopathic Thrombocytopenic Purpura  Academic Article
• Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient  Academic Article
• Eculizumab in a Patient with Dense-Deposit Disease  Academic Article
• Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12^*  Academic Article
• Evaluation of Subcutaneous Rituximab Administration on Canadian Systemic Therapy Suites  Academic Article
• Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma  Academic Article
• Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma  Conference Paper
• First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma  Academic Article
• Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura  Academic Article
• Hepatitis B, Rituximab, Screening, and Prophylaxis: Effectiveness and Cost Effectiveness  Academic Article
• ISTH guidelines for treatment of thrombotic thrombocytopenic purpura  Academic Article
• Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study  Academic Article
• Immunotherapies in Dermatologic Disorders  Academic Article
• Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma  Academic Article
• Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent  Academic Article
• In patients with rheumatoid arthritis, bDMARD therapy was not associated with malignant neoplasms  Academic Article
• Life-threatening hemolytic anemia due to an autoanti-Pr cold agglutinin: evidence that glycophorin A antibodies may induce lipid bilayer exposure and cation permeability independent of agglutination  Academic Article
• Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia  Academic Article
• Misleading hepatitis B test results due to intravenous immunoglobulin administration: implications for a clinical trial of rituximab in immune thrombocytopenia  Academic Article
• Mixed Variant Multicentric Castleman Disease Treated With Rituximab: Case Report  Academic Article
• Monoclonal gammopathy and glomerulopathy associated with chronic lymphocytic leukemia  Academic Article
• New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses  Academic Article
• Outcomes for transformed follicular lymphoma in the rituximab era: the Royal Marsden experience 2003–2013  Academic Article
• Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704  Academic Article
• Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma  Academic Article
• Physician decision making in selection of second-line treatments in immune thrombocytopenia in children  Academic Article
• Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis  Academic Article
• Plasma exchange and glucocorticoids to delay death or end-stage renal disease in anti-neutrophil cytoplasm antibody-associated vasculitis: PEXIVAS non-inferiority factorial RCT  Academic Article
• Positioning new treatments in the management of immune thrombocytopenia  Academic Article
• Prevalence and significance of large granular lymphocytes in patients with immune thrombocytopenia  Academic Article
• Pure red cell aplasia complicating B cell small lymphocytic lymphoma: a case report  Academic Article
• R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial  Academic Article
• Regulatory B10 Cells Increase after Rituximab Therapy but Not after Conventional Immunosuppression in Patients with Pemphigus  Academic Article
• Risk infection to spare bleeding? The quandary of splenectomy for immune thrombocytopenia  Academic Article
• Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis  Academic Article
• Rituximab for Sight-Threatening Lupus-Related Retinal Vasculitis  Academic Article
• Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline  Academic Article
• Rituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario  Academic Article
• Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid‐sparing effect  Academic Article
• Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpura  Academic Article
• Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis  Academic Article
• Rituximab utilization for approved and off‐label nononcology indications and patients’ experiences with the Patient Alert Card  Academic Article
• Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis  Academic Article
• Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial  Academic Article
• Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma  Academic Article
• Second‐line treatments in children with immune thrombocytopenia: Effect on platelet count and patient‐centered outcomes  Academic Article
• Splenectomy for immune thrombocytopenia: down but not out  Academic Article
• Successful treatment of multiply relapsed lymphoma with rituximab as a single agent  Academic Article
• Systematic Review: Efficacy and Safety of Rituximab for Adults with Idiopathic Thrombocytopenic Purpura  Academic Article
• Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin  Academic Article
• Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial  Academic Article
• The Completeness of Reporting (CORE) index identifies important deficiencies in observational study conference abstracts  Academic Article
• The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia  Academic Article
• The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases  Academic Article
• The effect of rituximab on vaccine responses in patients with immune thrombocytopenia  Academic Article
• The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura  Academic Article
• Thrombotic thrombocytopenic purpura in pediatric patients.  Academic Article
• Thrombotic thrombocytopenic purpura: 2008 Update  Academic Article
• Treatment Strategies in Elderly Patients with Aggressive Histology Lymphoma  Academic Article
• Treatment and its side effects in ANCA-associated vasculitides – Study based on POLVAS registry data  Academic Article
• Tubular Lesions Predict Renal Outcome in Antineutrophil Cytoplasmic Antibody–Associated Glomerulonephritis after Rituximab Therapy  Academic Article
• Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma  Academic Article
• Updates in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis: At a crossroad  Academic Article
• Use and Safety of Immunotherapeutic Management of N-Methyl-d-Aspartate Receptor Antibody Encephalitis  Academic Article
• Use of anti-CD20 antibody in the treatment of post-transplant glomerulonephritis  Academic Article